News|Articles|November 16, 2026

CHMP Recommends Dolutegravir, Dolutegravir/Lamivudine for Children With HIV

The CHMP has recommended expanding dolutegravir to term newborns weighing at least 2 kg and dolutegravir/lamivudine to children as young as 3 months, and European Commission decisions are expected in Q1 2027.

According to a new announcement from ViiV Healthcare, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanded pediatric use of two HIV therapies.¹ The opinions cover dolutegravir (Tivicay; ViiV Healthcare) and dolutegravir/lamivudine (DTG/3TC; Dovato; ViiV Healthcare) for younger children living with HIV.¹ If adopted, dolutegravir would be the first second-generation integrase strand transfer inhibitor (INSTI) in the EU for eligible term newborns, and DTG/3TC would become the first single-tablet, two-drug regimen for eligible younger children.¹

The European opinions follow the August 2026 FDA approval of dolutegravir (Tivicay PD) for children weighing at least 2 kg, including eligible term newborns, a decision also supported by IMPAACT 2023 data.² Globally, about half of untreated infants with HIV die by age two, and only 55% of children living with HIV received antiretroviral therapy in 2024.¹

For dolutegravir, the CHMP backed an extension of the existing dispersible tablet indication.¹ The drug, in combination with other antiretroviral agents, would be indicated for adults, adolescents, children, and term neonates from birth weighing at least 2 kg.¹ The current EU label covers patients 4 weeks or older weighing at least 3 kg.¹

For DTG/3TC, the committee recommended a new 5 mg/30 mg dispersible tablet formulation for children at least 3 months of age weighing 6 kg to less than 25 kg.¹ It also recommended extending the 50 mg/300 mg film-coated tablet indication to children weighing at least 20 kg.¹ The current EU indication is limited to adults and adolescents older than 12 years weighing at least 40 kg.¹

Both DTG/3TC recommendations apply only to patients with no known or suspected resistance to the INSTI class or lamivudine.¹ European Commission decisions on both applications are expected in the first quarter of 2027.¹ A pediatric New Drug Application for DTG/3TC is also under FDA review, with a Prescription Drug User Fee Act (PDUFA) date expected in the first quarter of 2027.¹

The Data Supporting Dolutegravir and DTG/3TC in Children Living With HIV

The dolutegravir application drew on IMPAACT 2023, a study sponsored by the Division of AIDS and funded by the National Institutes of Health.¹ Pharmacokinetic modeling incorporating additional pediatric data showed dolutegravir reaches therapeutic drug levels in term neonates.¹ No new safety findings emerged compared with older pediatric populations.¹

The DTG/3TC application relied on Penta-21, a pediatric and adult pharmacokinetic study sponsored by the PENTA Foundation, along with the DANCE study.¹ Regulators evaluated these data alongside extrapolated results from the adult GEMINI and TANGO trials, which support a favorable benefit/risk profile in treatment-naive and virologically suppressed pediatric populations.¹ Safety and tolerability for both agents were consistent with known profiles in older pediatric and adult patients; the announcement did not report hepatotoxicity signals or resistance emergence.¹

What You Need to Know

If adopted, the CHMP opinion would make dolutegravir the first second-generation INSTI in the EU for eligible term newborns weighing at least 2 kg, building on the FDA’s August 2026 approval of Tivicay PD for the same group.

A new dolutegravir/lamivudine dispersible tablet would give children at least 3 months old who weigh 6 kg to less than 25 kg their first single-tablet, two-drug regimen in the EU, as long as they have no known INSTI or lamivudine resistance.

Recent adult data back the pediatric expansion: dolutegravir/lamivudine was noninferior to bictegravir/emtricitabine/tenofovir alafenamide in the VOGUE trial, and updated HHS guidelines now recommend it regardless of baseline viral load.

The adult evidence base for DTG/3TC continued to grow this year. The phase 3b VOGUE trial, presented at AIDS 2026, randomized 509 treatment-naive adults to DTG/3TC or bictegravir/emtricitabine/tenofovir alafenamide.³ At week 48, 89% vs 92% achieved HIV-1 RNA below 50 copies/mL (adjusted difference, −3 percentage points; 95% CI, −8 to 2), meeting noninferiority.³ No treatment-emergent resistance occurred in either arm.³

Updated September 2026 US Department of Health and Human Services adult and adolescent guidelines now recommend DTG/3TC regardless of baseline plasma HIV viral load, based on the DOLCE study.⁴ The panel advises against DTG/3TC as a switch strategy for people with historical M184V/I mutations.⁴

“Children living with HIV require lifelong care, making continued innovation essential,” Jean van Wyk, MBChB, MFPM, chief medical officer at ViiV Healthcare, said in the announcement.¹ “These positive CHMP opinions mark an important step towards expanding age-appropriate, INSTI-based treatment options for children and advancing our goal of offering greater choice in HIV care.”¹

If the European Commission adopts both opinions, clinicians in the EU would gain INSTI-based options spanning birth through adolescence, including a single-tablet, two-drug regimen for children as light as 6 kg.¹ The pending FDA decision on pediatric DTG/3TC could bring a similar option to younger children in the US.¹

References
  1. ViiV Healthcare’s Tivicay and Dovato receive positive CHMP opinion for young children living with HIV, advancing efforts to close paediatric treatment gaps in the EU. News release. ViiV Healthcare; November 16, 2026.
  2. FDA approves Tivicay PD for infants with HIV. Contagion. August 26, 2026. Accessed November 16, 2026. https://www.contagionlive.com/view/fda-approves-tivicay-pd-for-infants-with-hiv
  3. Hoffman M. Dovato shows noninferior efficacy to Biktarvy in head-to-head HIV trial. Contagion. July 27, 2026. Accessed November 16, 2026. https://www.contagionlive.com/view/dovato-shows-noninferior-efficacy-to-biktarvy-in-head-to-head-hiv-trial
  4. Bender K. HHS updates guidelines for antiretroviral treatment of HIV. Contagion. October 18, 2026. Accessed November 16, 2026. https://www.contagionlive.com/view/hhs-updates-guidelines-for-antiretroviral-treatment-of-hiv

Related to this article

FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.